EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Comparison of the Clinical Response in Total Neoadjuvant Treatment With Long‐Term or Short‐Term Chemoradiotherapy Followed by Consolidation Chemotherapy in Patients With Locally Advanced Rectal Cancer ( TEHRAN ); the Protocol for a Randomized Controlled Clinical Trial

Mahdi Aghili, Reza Ghalehtaki iD, Mahdiyeh Yaghooti-Khorasani, Seyed Masoud Miratashi Yazdi, Kasra Kolahdouzan iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71472 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Cancer Medicine, 2025. Verfasst von Mahdi Aghili und 4 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Consolidation Chemotherapy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tehran University of Medical Sciences and Health Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Total neoadjuvant therapy (TNT) is a preferred method for the treatment of locally advanced rectal cancer (LARC). Two techniques of radiotherapy have been used in TNT trials so far, including long‐course chemoradiotherapy (LCRT) and short‐course radiotherapy (SCRT). However, to date, no study compares these techniques in a head‐to‐head fashion. Our objective is to compare the complete clinical response among patients with LARC who receive long or short‐course radiation therapy in combination with the same chemotherapy regimen.

Methods

158 patients (18–80 years old) with standard or high‐risk LARC (T3/T4 tumor or lymph node positive) located at least 5 cm from the anal verge will be randomized into two groups: LCRT (with a dose of 50.4 Gy in 28 sessions) or SCRT (with a dose of 25 Gy in five sessions). Both of these groups will receive concurrent chemotherapy (capecitabine 825 mg/m 2 twice daily) followed by consolidation chemotherapy with the CAPEOX regimen for 6 cycles or mFOLFOX7 for 9 cycles. We will compare the complete clinical response (initially 12–16 weeks after the last RT fraction and eventually 2 weeks after the last chemotherapy cycle) by MRI as the primary endpoint. Overall survival (OS), metastasis‐free survival (MFS), local control, and toxicities will be evaluated after 3–5 years as the secondary endpoints.

Discussion

Advances in the treatment of rectal cancer focus on metastasis control, besides local control by using neoadjuvant therapy. Determining the complete clinical response, OS, and MFS of short‐course versus long‐course chemoradiation will assist in choosing the best LARC treatment protocol. Trial Registration ClinicalTrials.gov : NCT05920928, 2023.06.27

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsConsolidation ChemotherapyChemoradiotherapyHumansMiddle AgedAdultAgedFemaleMaleAged, 80 and overYoung AdultAdolescentRandomized Controlled Trials as TopicTreatment OutcomeOxaliplatinCapecitabine

Stichwörter der Autor:innen

chemotherapyneoadjuvantradiotherapyrectal cancer

Substanzen

OxaliplatinCapecitabine

Autor:innen und Institutionen

  • Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Reza Ghalehtaki, Kasra Kolahdouzan

Förderung

  • Tehran University of Medical Sciences and Health Services

Zitieren

APA

Aghili, M., Ghalehtaki, R., Yaghooti-Khorasani, M., Yazdi, S. M. M., & Kolahdouzan, K. (2025). Comparison of the Clinical Response in Total Neoadjuvant Treatment With Long‐Term or Short‐Term Chemoradiotherapy Followed by Consolidation Chemotherapy in Patients With Locally Advanced Rectal Cancer ( TEHRAN ); the Protocol for a Randomized Controlled Clinical Trial. Cancer Medicine. https://doi.org/10.1002/cam4.71472

Vancouver

Aghili M, Ghalehtaki R, Yaghooti-Khorasani M, Yazdi SMM, Kolahdouzan K. Comparison of the Clinical Response in Total Neoadjuvant Treatment With Long‐Term or Short‐Term Chemoradiotherapy Followed by Consolidation Chemotherapy in Patients With Locally Advanced Rectal Cancer ( TEHRAN ); the Protocol for a Randomized Controlled Clinical Trial. Cancer Medicine. 2025. doi:10.1002/cam4.71472

BibTeX
@article{Aghili2025,
  author = {Aghili, Mahdi and Ghalehtaki, Reza and Yaghooti-Khorasani, Mahdiyeh and Yazdi, Seyed Masoud Miratashi and Kolahdouzan, Kasra},
  title = {Comparison of the Clinical Response in Total Neoadjuvant Treatment With Long‐Term or Short‐Term Chemoradiotherapy Followed by Consolidation Chemotherapy in Patients With Locally Advanced Rectal Cancer ( TEHRAN ); the Protocol for a Randomized Controlled Clinical Trial},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71472}
}
Kostenlos starten →